Grepafloxacin: Pharmacokinetics and tissue penetration

Clinical Microbiology and Infection

Volumn 4, Issue SUPPL. 1, 1998, Pages

  Wise, Richard ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

Fluoroquinolone; Grepafloxacin; Pharmacokinetics; Respiratory tract infection; Tissue penetration

Indexed keywords

GREPAFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AREA UNDER THE CURVE; BRONCHUS MUCOSA; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG PENETRATION; ENTEROCOCCUS FAECALIS; LUNG ALVEOLUS MACROPHAGE; MORAXELLA CATARRHALIS; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0031981672     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1998.tb00685.x     Document Type: Conference Paper

References (16)

1. Wolfon JS, Hooper DC. Pharmacokinetics of quinolones: newer aspects. Eur J Clin Microbiol Infect Dis 1991; 10: 267-74.
2. Child J, Andrews JM, Wise R. Pharmacokinetics and tissue penetration of the new fluoroquinolone, grepafloxacin. Antithromb Agents Chemother 1995; 39: 513-15.
3. Efthymiopoulos C, Bramer SL, Maroli A. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. Clin Pharmacokinet 1997; 33(suppl 1): 1-8.
4. Vance-Bryan K, Guay DRP, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 1990; 19: 434-61.
5. Johnson JH, Cooper MH, Andrews JM, Wise R. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother 1992; 36: 2444-6.
6. Lamp KC, Bailey EM, Rybak MJ. Ofloxacin clinical pharmacokinetics. Clin Pharmacokinet 1992; 22: 32-46.
7. Neu HC, Fang W, Gu JW, Chin NX. In vitro activity of OPC-17116. Antimicrob Agents Chemother 1992; 6: 1310-15.
8. Sader HS, Erwin ME, Jones RN. In vitro activity of OPC-17116 compared to other broad spectrum fluoroquinolones. Eur J Clin Microbiol Infect Dis 1992; 11: 372-81.
9. Efthymiopoulos C. Pharmacokinetics of grepafloxacin. J Antimicrob Chemother 1997; 40: 35-43.
10. Taira K, Koga H, Kohno S. Accumulation of a newly developed fluoroquinolone, OPC-17116, by human polymorphonuclear leukocytes. Antimicrob Agent Chemother 1993; 37(9): 1877-81.
11. Cook PJ, Andrews JM, Wise R, Honeybourne D, Moudgil H. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother 1995; 35: 317-26.
12. Pankuch G, Jacobs M, Appelbaum P. Antipneumococcal activity of grepafloxacin compared to 5 other agents by time-kill [abstract]. 37th ICAAC, Toronto, Canada, 1997.
13. Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989; 2: 378-424.
14. Honeybourne D. Antibiotic penetration into lung tissues. Thorax 1994; 49: 104-6.
15. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. The pharmacodynamics of intravenous ciprofloxacin in seriously ill patients Antimicrob Agents Chemother 1993; 37: 1073-81.
16. Drusano G. Pharmacodynamics of quinolones. JAMA 1998 (in press).